Renfu Pharmaceuticals (600079.SH): HW231019 tablets entered Phase II clinical trial research.

Zhtng Cijng APP news, Renfu Pharmaceuticals (600079.SH) announced that the company's controlling subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu," the company holds 80% of its equity), recently disclosed the registration information of the HW231019 tablet phase II clinical trial on the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform.